SCHEMBL2483465

SCHEMBL2483465

NC(=O)c1cnc(Nc2ccncc2)cc1NCc1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 11/20 0.86
▸ IRAK4 Q9NWZ3 6/20 0.86
▸ JAK2 O60674 3/20 0.86
▸ JAK1 P23458 3/20 0.86
▸ TYK2 P29597 3/20 0.86
▸ CSF1R P07333 1/20 0.65
▸ BTK Q06187 1/20 0.65
▸ CDC7 O00311 1/20 0.59
▸ ROCK2 O75116 1/20 0.59
▸ MAP4K4 O95819 1/20 0.59
▸ GSK3B P49841 1/20 0.59
▸ CLK4 Q9HAZ1 1/20 0.59
▸ MKNK2 Q9HBH9 1/20 0.59
▸ KDM4E B2RXH2 1/20 0.50
▸ KDM6B O15054 1/20 0.50
▸ KDM4A O75164 1/20 0.50
▸ KDM4D Q6B0I6 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.50
▸ RPS6KB1 P23443 2/20 0.48
▸ AKT1 P31749 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2479678 0.93 JAK3 (1.00) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12321879 0.89 JAK3 (0.76) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2485746 0.88 JAK3 (0.86) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2478357 0.88 JAK3 (0.86) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12321884 0.88 JAK3 (1.00) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2696991 0.87 JAK3 (0.84) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2692957 0.87 JAK3 (0.84) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2478203 0.87 JAK3 (0.84) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12301732 0.86 JAK3 (0.83) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2696040 0.86 JAK3 (0.71) JAK3IRAK4JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102227409-B Pyridine-3-carboxyamide derivative KOWA CO 2014-03-26 — — CN claimed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US claimed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP claimed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 — — CN claimed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US claimed
CN-102227409-B Pyridine-3-carboxyamide derivative KOWA CO 2014-03-26 — — CN disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 — — CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA JAK3 1/4885IRAK4 128/4885JAK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback